| Literature DB >> 35434602 |
Jia Jin Hiu1, Michelle Khai Khun Yap1,2.
Abstract
Cobra venom cytotoxin (CTX) is a non-enzymatic three-finger toxin that constitutes 40-60% of cobra venom. Thus, it plays an important role in the pathophysiology of cobra envenomation, especially in local dermonecrosis. The three-finger hydrophobic loops of CTX determine the cytotoxicity. Nevertheless, the actual mechanisms of cytotoxicity are not fully elucidated as they involve not only cytolytic actions but also intracellular signalling-mediated cell death pathways. Furthermore, the possible transition cell death pattern remains to be explored. The actual molecular mechanisms require further studies to unveil the relationship between different CTXs from different cobra species and cell types which may result in differential cell death patterns. Here, we discuss the biophysical interaction of CTX with the cell membrane involving four binding modes: electrostatic interaction, hydrophobic partitioning, isotropic phase, and oligomerisation. Oligomerisation of CTX causes pore formation in the membrane lipid bilayer. Additionally, the CTX-induced apoptotic pathway can be executed via death receptor-mediated extrinsic pathways and mitochondrial-mediated intrinsic pathways. We also discuss lysosomal-mediated necrosis and the occurrence of necroptosis following CTX action. Collectively, we provided an insight into concentration-dependent transition of cell death pattern which involves different mechanistic actions. This contributes a new direction for further investigation of cytotoxic pathways activated by the CTXs for future development of biotherapeutics targeting pathological effects caused by CTX.Entities:
Keywords: Apoptosis; Cytolytic; Cytotoxin; Necroptosis; Necrosis
Year: 2022 PMID: 35434602 PMCID: PMC9011113 DOI: 10.1016/j.toxcx.2022.100123
Source DB: PubMed Journal: Toxicon X ISSN: 2590-1710
Fig. 1The authors constructed the structure of cytotoxin (CTX) using MODELLER v9.20. The basic residues are annotated in red colour, while the disulphide bridges are annotated as green colour stick formation. It is a highly basic polypeptide consisting of 60–62 amino acid residues and it is stabilised by disulphide bonds. Like other three-finger toxins, its secondary structure comprises anti-parallel β-pleated sheets that form three hydrophobic loops, with asymmetric distribution of non-polar and polar amino acid residues. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Cytotoxicity of various cytotoxins from different cobra species against different normal cell lines.
| Species | CTX type | Cell types | IC50/LD50 | References |
|---|---|---|---|---|
| CTX III | H9C2 rat cardiomyocyte cells | 2 μM | ||
| NA | MDCK normal dog kidney cells | 47.1 μg/mL | ||
| L929 normal mouse fibroblast cells | NA | |||
| P-type CTX | RWPE-1 prostate epithelial cells | 0.35 ± 0.08 μg/mL | ||
| 184B5 breast epithelial cells | 6.21 ± 0.37 μg/mL | |||
| NL20 lung epithelial cells | 1.91 ± 0.52 μg/mL | |||
| S-type CTX | RWPE-1 prostate epithelial cells | 0.65 ± 0.20 μg/mL | ||
| 184B5 breast epithelial cells | 2.83 ± 0.34 | |||
| NL20 lung epithelial cells | 2.76 ± 0.49 | |||
| CTX-1N | mouse red blood cells (RBC) | >90 μM | ||
| CTX-2N | mouse red blood cells (RBC) | 45 ± 3 μM | ||
| CTX-3N | mouse red blood cells (RBC) | NA | ||
| CTX-4N | mouse red blood cells (RBC) | >90 μM |
Cytotoxicity of various cytotoxins from different cobra species against different cancer cell lines.
| Species | CTX type | Cell types | IC50/LD50 | References |
|---|---|---|---|---|
| CTX III | K562 human leukaemia cells | 1.7 μg/mL | ||
| Human leukemic T-lymphocytes | 2 μM | |||
| CAL27 oral squamous carcinoma cells | 0.28 μM | |||
| SAS human tongue carcinoma cells | 0.35 μM | |||
| Ca9-22 oral squamous carcinoma cells | 0.15 μM | |||
| CTX I | A549 human lung adenocarcinoma cells | 132 ± 9 μg/mL | ||
| HL60 promyelocytic leukaemia cells | 2.6 ± 0.1 μg/mL | |||
| CTX II | A549 human lung adenocarcinoma cells | 116 ± 6 μg/mL | ||
| HL60 promyelocytic leukaemia cells | 1.9 ± 0.1 μg/mL | |||
| CTX III | K562 human leukaemia cells | 2.63 μg/mL | ||
| MDA-MB-231 human breast cancer cell line | NA | |||
| NN-32 | U937 cell human leukaemia cells | NA | ||
| CTX I | A549 human lung adenocarcinoma cells | 16.6 ± 0.6 μg/mL | ||
| HL60 promyelocytic leukaemia cells | 0.58 ± 0.03 μg/mL | |||
| CTX II | A549 human lung adenocarcinoma cells | 1.7 ± 0.1 μg/mL | ||
| HL60 promyelocytic leukaemia cells | 0.33 ± 0.02 μg/mL | |||
| K562 human leukaemia cells | NA | |||
| CTX | HepG2 human hepatocellular carcinoma cells | 26.59 μg/mL | ||
| MCF-7 human breast cancer cells | 28.85 μg/mL | |||
| DU145 human prostate carcinoma cells | 21.17 μg/mL | |||
| P-type CTX | A549 lung cancer epithelial cells | 0.88 ± 0.06 μg/mL | ||
| PC-3 prostate epithelial cells | 3.13 ± 0.58 μg/mL | |||
| MCF-7 breast cancer cells | 3.89 ± 0.39 μg/mL | |||
| S-type CTX | A549 lung cancer epithelial cells | 1.22 ± 0.09 μg/mL | ||
| PC-3 prostate epithelial cells | 4.46 ± 0.36 μg/mL | |||
| MCF-7 breast cancer cells | 12.23 ± 0.74 μg/mL | |||
| HL60 promyelocytic leukaemia cells | 0.18 ± 0.01 μg/mL | |||
| CTX I | U937 human leukaemia cells | 3.5 μg/mL | ||
| K562 human leukaemia cells | 1.1 μg/mL | |||
| CTX-1N | A549 non-small cell lung adenocarcinoma cells | 0.8 ± 0.2 μM | ||
| MDA-MB-231 breast adenocarcinoma cells | 7 ± 1 μM | |||
| HT-29 colorectal adenocarcinoma cells | 9 ± 1 μM | |||
| HUVEC human umbilical vein endothelial cells | 7 ± 1 μM | |||
| CTX-2N | A549 non-small cell lung adenocarcinoma cells | 1.4 ± 0.2 μM | ||
| MDA-MB-231 breast adenocarcinoma cells | 6 ± 1 μM | |||
| HT-29 colorectal adenocarcinoma cells | 8 ± 1 μM | |||
| human umbilical vein endothelial HUVEC cells | 7 ± 1 μM | |||
| CTX-3N | A549 non-small cell lung adenocarcinoma cells | 7 ± 1 μM | ||
| MDA-MB-231 breast adenocarcinoma cells | >30 μM | |||
| HT-29 colorectal adenocarcinoma cells | >30 μM | |||
| HUVEC human umbilical vein endothelial cells | 22 ± 2 μM | |||
| CTX-4N | A549 non-small cell lung adenocarcinoma cells | 0.9 ± 0.2 μM | ||
| MDA-MB-231 breast adenocarcinoma cells | 8 ± 1 μM | |||
| HT-29 colorectal adenocarcinoma cells | 25 ± 3 μM | |||
| HUVEC human umbilical vein endothelial cells | 2 ± 0.2 μM | |||
| CTX | Human histiocytic lymphoma U-937 cells | 126.80 ± 2.94 mg/L/1 × 10^6 cells | ||
| HL60 promyelocytic leukaemia cells | 121.29 ± 1.42 mg/L/1 × 10^6 cells |
Fig. 2The percentage of cytotoxin in different cobra venom from diverse geographical locations. On average, 47% of cobra venom's dry weight consists of cytotoxin. The percentage of cytotoxin is acquired from the venomics profile of different cobra species (Asad et al., 2019; Beraldo et al., 2021; Chanda et al., 2018; Choudhury et al., 2017; Huang et al., 2015; Lauridsen et al., 2017; Liu et al., 2017; Malih et al., 2014; Petras et al., 2011; Shan et al., 2016; Sintiprungrat et al., 2016; Tan et al., 2015b; Tan et al., 2017, 2019, 2020; Wong et al., 2018, 2021; Xu et al., 2017; Yap et al., 2014).
Fig. 3A summary of the mechanistic actions of cobra venom cytotoxin (CTX) was created using BioRender.com. The basic hydrophobic loops of CTX interact with the phospholipid bilayer and destabilise cell membranes for cytolysis. Nevertheless, various intracellular cell death signalling pathways have been targeted by CTX. Cytotoxin triggers Ca2+ influx and activation of the Ca2+/PP2A/AMPK pathway. This causes mitochondrial fragmentation. Furthermore, the internalised CTX following membrane permeabilisation could also co-localise at mitochondria to stimulate intrinsic mitochondrial-mediated apoptosis. Cytochrome c is then released following deprivation of mitochondrial membrane integrity and bind to APAF 1, which then recruits caspase-9 to form an apoptosome. The apoptosome activates the executioner caspase-3 for intrinsic apoptosis. Apoptosis is also associated with upregulation of proapoptotic proteins and inactivation of EFGR, Pl3K/Akt, and JAK/STAT3 pathways. In addition, CTX also induces extrinsic apoptosis involving Fas receptors. In addition, intracellular accumulation of Ca2+ activates NOX4 expression, a major contributor to oxidative stress which triggers p38 MAPK/cJUN/ATF-2 apoptosis pathways. Cell cycle arrest is a downstream cytotoxic effect of CTX. On the other hand, lysosomal-associated necrosis has also been reported for CTX-induced cell death, attributed to highly elevated cathepsin B following lysosomal membrane permeabilisation. Besides necrosis, CTX also induces caspase-independent, regulated necroptosis involving activation of TNFR1-RIPK signalling cascades, which is also associated with upregulation of antiapoptotic proteins such as HSP90AA1, HSP90AB1 and PPIA.